Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158421 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kamal U Saikh und 6 weiteren Autor:innen. Beteiligte Einrichtung: GlycoMantra Inc., bwtech South of the University of Maryland Baltimore County, 1450 South Rolling Road, Baltimore, MD 21227, USA. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, SARS-CoV-2, COVID-19, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Nearly six million people worldwide have died from the coronavirus disease (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although COVID-19 vaccines are largely successful in reducing the severity of the disease and deaths, the decline in vaccine-induced immunity over time and the continuing emergence of new viral variants or mutations underscore the need for an alternative strategy for developing broad-spectrum host-mediated therapeutics against SARS-CoV-2. A key feature of severe COVID-19 is dysregulated innate immune signaling, culminating in a high expression of numerous pro-inflammatory cytokines and chemokines and a lack of antiviral interferons (IFNs), particularly type I (alpha and beta) and type III (lambda). As a natural host defense, the myeloid differentiation primary response protein, MyD88, plays pivotal roles in innate and acquired immune responses via the signal transduction pathways of Toll-like receptors (TLRs), a type of pathogen recognition receptors (PRRs). However, recent studies have highlighted that infection with viruses upregulates MyD88 expression and impairs the host antiviral response by negatively regulating type I IFN. Galectin-3 (Gal3), another key player in viral infections, has been shown to modulate the host immune response by regulating viral entry and activating TLRs, the NLRP3 inflammasome, and NF-κB, resulting in the release of pro-inflammatory cytokines and contributing to the overall inflammatory response, the so-called “cytokine storm”. These studies suggest that the specific inhibition of MyD88 and Gal3 could be a promising therapy for COVID-19. This review presents future directions for MyD88- and Gal3-targeted antiviral drug discovery, highlighting the potential to restore host immunity in SARS-CoV-2 infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GlycoMantra Inc., bwtech South of the University of Maryland Baltimore County, 1450 South Rolling Road, Baltimore, MD 21227, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- NIH HHS
- Defense Threat Reduction Agency (DTRA)
- Concept Award from the US Army Medical Research and Materiel Command
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Saikh, K. U., Anam, K., Sultana, H., Ahmed, R., Kumar, S., Srinivasan, S., & Ahmed, H. (2024). Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158421
Vancouver
Saikh KU, Anam K, Sultana H, Ahmed R, Kumar S, Srinivasan S, et al. Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158421
BibTeX
@article{Saikh2024,
author = {Saikh, Kamal U and Anam, Khairul and Sultana, Halima and Ahmed, Rakin and Kumar, Simran and Srinivasan, Sanjay and Ahmed, Hafiz},
title = {Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158421}
}
EUVIMED